Table 1.
Demographics and baseline characteristics of all R/R FL and DLBCL patients (safety population)
| R/R FL G-atezo-pola |
R/R DLBCL R-atezo-pola |
||
|---|---|---|---|
| Pola 1.4 mg/kg (N = 3) |
Pola 1.8 mg/kg (N = 10) |
Pola 1.8 mg/kg (N = 21) |
|
| Median age, years (range) | 54 (38–65) | 58.5 (31–71) | 68 (21–92) |
| Male, n (%) | 3 (100) | 6 (60) | 13 (62) |
| Ann Arbor stage at diagnosis (III–IV), n (%) | 2 (67) | 9 (90) | 18 (86) |
| FLIPI score, n (%) | |||
| 0–1 (low risk) | 2 (67) | 3 (30) | – |
| 2 (intermediate risk) | 1 (33) | 1 (10) | – |
| 3–5 (high risk) | 0 | 6 (60) | – |
| IPI score, n (%) | |||
| 0–2 (low risk) | – | – | 7 (33) |
| 3–5 (intermediate-to-high risk) | – | – | 14 (67) |
| ECOG PS 0–1, n (%) | 3 (100) | 10 (100) | 18 (86) |
| Bulky disease (> 7.5 cm), n (%) | 0 | 6 (60) | 6 (29) |
| Bone marrow infiltration, n (%) | 0 | 2 (20) | 4 (20) |
| Extranodal involvement, n (%) | 1 (33) | 7 (70) | 16 (76) |
| Elevated LDH, n (%) | 0 | 2 (20) | 15 (71) |
| Refractory to last line, n (%) | 1 (33) | 8 (80) | 20 (95) |
| Relapsed on last line, n (%) | 2 (67) | 2 (20) | 1 (5) |
| Median prior lines of therapy (range) | 2 (1–5) | 2 (1–4) | 2 (1–8) |
| Prior stem cell transplant, n (%) | 0 | 1 (10) | 6 (29) |
Atezo atezolizumab, DLBCL diffuse large B-cell lymphoma, ECOG PS Eastern Cooperative Oncology Group performance status, FL follicular lymphoma, FLIPI Follicular Lymphoma International Prognostic Index, G obinutuzumab, IPI International Prognostic Index, LDH lactate dehydrogenase, pola polatuzumab vedotin, R rituximab, R/R relapsed/refractory